Stephen H. Shoemaker - 08 Aug 2025 Form 4 Insider Report for 180 Life Sciences Corp. (ATNF)

Reporting relationship: Director
Issuer ticker: ATNF
Reported as of: 08 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Aug 2025, 19:48:09 UTC
Prior SEC filing: 07 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Stephen H. Shoemaker

Key filing fact

Stephen H. Shoemaker filed Form 4 for 180 Life Sciences Corp. (ATNF) on 11 Aug 2025.

Key facts

This page summarizes Stephen H. Shoemaker's Form 4 filing for 180 Life Sciences Corp. (ATNF).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Aug 2025, 19:48.

Change

Previous filing in this sequence was filed on 07 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002048098 Primary reporting owner

Shoemaker Stephen H

Relationship: Director
Address: 3000 EL CAMINO REAL, BLDG. 4,, SUITE 200, PALO ALTO
Signature: /s/ Stephen H. Shoemaker
Signature date: 11 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATNF holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 132,439
Date: 08 Aug 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATNF transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value: $0
Shares: +181,422
Change %
Price: $0.000000
Shares after: 181,422
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 181,422
Exercise price: $3.01
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The options were granted under the 2025 Second Supplemental Option Plan of the Issuer. The options vested immediately, but are not exercisable until stockholder approval of the 2025 Second Supplemental Option Plan is received. If stockholder approval is not received prior to August 8, 2026, the options will be cancelled.

Footnote F2

Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a director of the Issuer.